Michael P. Cooke

Michael P. Cooke

Auto-generated profile, based on publicly available information

Michael P. Cooke

The Genomics Institute of Novartis Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA.

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2010 in Science
Verified
Journal Article
Closed access
PDF file
ABAnthony E. Boitano
Anthony E. Boitano
JWJian Wang
Jian Wang
RRRussell Romeo
Russell Romeo
LBLaure C. Bouchez
Laure C. Bouchez
APAlbert E. Parker
Albert E. Parker
MCMichael P. Cooke
Michael P. Cooke
Stem Cell Expansion: The ability to expand hematopoietic stem cells (HSCs) during ex-vivo culture has been an important goal for over 20 years. Using a high-throughput chemical screen, Boitano et al. (p. 1345 , published online 5 August; see the Perspective by Sauvageau and Humphries ) found that a purine derivative, StemRegenin1 (SR1), promoted the expansion of human HSCs. Treatment of HSCs with SR1 (which blocked the activity of the aryl hydrocarbon receptor) led to the expansion of CD34 + cells and a 12 to 17-fold increase in the number of HSCs that engraft immune deficient mice.

19 November 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
TWTom Y.-H. Wu
Tom Y.-H. Wu
MSManmohan Singh
Manmohan Singh
AMAndrew T. Miller
Andrew T. Miller
EGEnnio De Gregorio
Ennio De Gregorio
FDFrancesco Doro
Francesco Doro
NVNicholas M. Valiante
Nicholas M. Valiante
Small-molecule immune potentiators can be engineered to be potent adjuvants with localized innate immune activation and short in vivo residence times.

24 December 2012 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DBDaniel R. Beisner
Daniel R. Beisner
PLPetra Langerak
Petra Langerak
APAlbert E. Parker
Albert E. Parker
CDCarol Dahlberg
Carol Dahlberg
FOFrancella J. Otero
Francella J. Otero
MCMichael P. Cooke
Michael P. Cooke
B cell development requires tight regulation to allow for the generation of a diverse repertoire while preventing the development of autoreactive cells. We report, using N-ethyl-N-nitrosourea (ENU)–induced mutagenesis, the identification of a mutant mouse (chompB) with a block in early B cell development. The blockade occurs after the transitional 1 (T1) stage and leads to a decrease in mature B cell subsets and deficits in T cell–dependent antibody responses. Additionally, chompB mice have decreases in myeloid dendritic cells (DCs). The mutation was mapped to the intramembrane protease signal peptide peptidase-like 2a (Sppl2a), a gene not previously implicated in immune cell development. Proteomic analysis identified the invariant chain (CD74) as a key substrate of Sppl2a and suggests that regulated intramembrane proteolysis of CD74 by Sppl2a contributes to B cell and DC survival. Moreover, these data suggest that modulation of Sppl2a may be a useful therapeutic strategy for treatment of B cell dependent autoimmune disorders.

30 March 2011 in Immunology Letters
Verified
Journal Article
Closed access
Laura B. RamseyLaura B. Ramsey
Laura B. Ramsey
AVAmanda L. Vegoe
Amanda L. Vegoe
AMAndrew T. Miller
Andrew T. Miller
MCMichael P. Cooke
Michael P. Cooke
MFMichael A. Farrar
Michael A. Farrar